Overview
BHVN market data
Price History
BHVN price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for BHVN. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On FridayBenzinga · Jul 17, 2026, 2:09 PM
8-K filing — Biohaven Ltd. (BHVN)SEC EDGAR · Jul 9, 2026, 9:11 PM
Biohaven Completes Enrollment In RISE3 Trial To Evaluate Opakalim Channel Activator To Treat Refractory Focal EpilepsyBenzinga · Jun 30, 2026, 11:35 AM
Analyst Warns Biohaven's Lead Drug May Struggle To Stand OutBenzinga · Jun 29, 2026, 6:10 PM
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market SessionBenzinga · Jun 29, 2026, 12:15 PM
B of A Securities Downgrades Biohaven to Underperform, Lowers Price Target to $11Benzinga · Jun 29, 2026, 11:50 AM
Biohaven Announces Enrollment Of First Patient In Its Pivotal Phase 3 Trial Of BHV-1300 For Graves' DiseaseBenzinga · Jun 29, 2026, 11:40 AM
Biohaven Initiates First-In-Human Dosing For BHV-8100 Pyruvate Kinase M2 Isoform ModulatorBenzinga · Jun 1, 2026, 11:31 AM
Biohaven Presents New Patient Data From Its BHV-1300 MoDE Degrader For Graves' Disease, BHV-1400 Trap Degrader For IgA NephropathyBenzinga · May 27, 2026, 11:34 AM
HC Wainwright & Co. Reiterates Neutral on Biohaven, Maintains $10 Price TargetBenzinga · May 26, 2026, 4:34 PM